title: Ð¥Ð°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐ° ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÑ Ð±ÐµÐ»ÐºÐ¾Ð² Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ SAP, Ð½ÐµÑÑÑÐ¸Ñ ÐºÐ¾Ð½ÑÐµÑÐ²Ð°ÑÐ¸Ð²Ð½ÑÐµ ÑÑÐ°Ð³Ð¼ÐµÐ½ÑÑ Ð±ÐµÐ»ÐºÐ¾Ð² Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° Ð
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Characterization of SAP-based recombinant proteins carrying conserved fragments of influenza A virus proteins
Creators: name: ÐÐ¶ÐµÑÐµÐ»ÑÐµÐ²Ð°, ÐÐ»ÑÐ³Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2022
Subjects: ÐÐµÐ»ÐºÐ¸
ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÐµ Ð±ÐµÐ»ÐºÐ¸
ÑÐ½Ð¸Ð²ÐµÑÑÐ°Ð»ÑÐ½ÑÐµ Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½ÑÐµ Ð²Ð°ÐºÑÐ¸Ð½Ñ
recombinant proteins
universal influenza vaccine

description: Ð¢ÐµÐ¼Ð° Ð²ÑÐ¿ÑÑÐºÐ½Ð¾Ð¹ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ: Â«Ð¥Ð°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐ° ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÑ Ð±ÐµÐ»ÐºÐ¾Ð² Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ SAP, Ð½ÐµÑÑÑÐ¸Ñ ÐºÐ¾Ð½ÑÐµÑÐ²Ð°ÑÐ¸Ð²Ð½ÑÐµ ÑÑÐ°Ð³Ð¼ÐµÐ½ÑÑ Ð±ÐµÐ»ÐºÐ¾Ð² Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° AÂ». Ð ÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÐµ Ð±ÐµÐ»ÐºÐ¸ Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ SAP, Ð¸ÑÑÐ»ÐµÐ´ÑÐµÐ¼ÑÐµ Ð² ÑÐ°Ð±Ð¾ÑÐµ, Ð²ÐºÐ»ÑÑÐ°Ð»Ð¸ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ðµ ÑÐµÐ»ÐµÐ²ÑÐµ Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ñ: ÑÐºÑÐ¾Ð´Ð¾Ð¼ÐµÐ½ Ð±ÐµÐ»ÐºÐ° Ð2 (Ð2Ðµ), ÑÑÐ°Ð³Ð¼ÐµÐ½Ñ Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð° (HA) Ð°Ðº 76-130 Ð¸ 2 ÑÑÐ°Ð³Ð¼ÐµÐ½ÑÐ° Ð±ÐµÐ»ÐºÐ° NP â Ð°Ðº 255-275 Ð¸ Ð°Ðº 335-350. ÐÑÐ»Ð¸ ÑÐºÐ¾Ð½ÑÑÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ñ 4 Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ° ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÑ Ð±ÐµÐ»ÐºÐ¾Ð²: NP(-), NP(255), NP(335) Ð¸ NP(335+255). ÐÑÐ»Ð° Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð° ÑÐ¸Ð·Ð¸ÐºÐ¾-ÑÐ¸Ð¼Ð¸ÑÐµÑÐºÐ°Ñ ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐ° ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÑ Ð±ÐµÐ»ÐºÐ¾Ð². ÐÐ¾ ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐ°Ð¼ Ð¿ÑÐµÐ´ÑÐºÐ°Ð·Ð°Ð½Ð¸Ñ Ð²ÑÐ¾ÑÐ¸ÑÐ½Ð¾Ð¹ Ð¸ ÑÑÐµÑÐ¸ÑÐ½Ð¾Ð¹ ÑÑÑÑÐºÑÑÑÑ Ð² ÑÐµÑÐ²ÐµÑÐ°Ñ PSIPRED Ð¸ Ð¡-QUARK Ð±ÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ ÑÑÐ°Ð³Ð¼ÐµÐ½ÑÑ SAP Ð¸ ÐÐ76-130 Ð½Ðµ Ð¿Ð¾Ð»Ð½Ð¾ÑÑÑÑ ÑÐ¾ÑÑÐ°Ð½ÑÑÑ ÑÐ²Ð¾Ñ Ð½Ð°ÑÐ¸Ð²Ð½ÑÑ ÑÑÑÑÐºÑÑÑÑ Ð² ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÑ Ð±ÐµÐ»ÐºÐ°Ñ. ÐÐ¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ Ð¼Ð¾Ð»ÐµÐºÑÐ»ÑÑÐ½Ð°Ñ Ð¼Ð°ÑÑÐ° Ð±ÐµÐ»ÐºÐ¾Ð² Ð¿Ð¾ Ð¸Ñ ÑÐ»ÐµÐºÑÑÐ¾ÑÐ¾ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ Ð¿Ð¾Ð´Ð²Ð¸Ð¶Ð½Ð¾ÑÑÐ¸ ÑÐ¾Ð¾ÑÐ²ÐµÑÑÑÐ²ÑÐµÑ Ð¸Ñ ÑÐµÐ¾ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ Ð¼Ð¾Ð»ÐµÐºÑÐ»ÑÑÐ½Ð¾Ð¹ Ð¼Ð°ÑÑÐµ. ÐÐµÐ»ÐºÐ¸ Ð¾Ð±Ð»Ð°Ð´Ð°ÑÑ Ð´Ð¾ÑÑÐ°ÑÐ¾ÑÐ½Ð¾Ð¹ ÑÑÐµÐ¿ÐµÐ½ÑÑ Ð¾ÑÑÐ¸ÑÑÐºÐ¸. ÐÑÑÐ²Ð»ÐµÐ½Ð¾, ÑÑÐ¾ Ð³Ð¸Ð´ÑÐ¾Ð´Ð¸Ð½Ð°Ð¼Ð¸ÑÐµÑÐºÐ¸Ð¹ Ð´Ð¸Ð°Ð¼ÐµÑÑ ÑÐ°ÑÑÐ¸Ñ, Ð¾Ð±ÑÐ°Ð·ÑÐµÐ¼ÑÑ Ð¸ÑÑÐ»ÐµÐ´ÑÐµÐ¼ÑÐ¼Ð¸ Ð±ÐµÐ»ÐºÐ°Ð¼Ð¸, ÑÐ¾ÑÑÐ°Ð²Ð¸Ð» Ð¾Ñ 47 Ð´Ð¾ 107 Ð½Ð¼. Ð ÐµÐ·ÑÐ»ÑÑÐ°ÑÑ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð¸Ð¼Ð¼ÑÐ½Ð¾Ð³ÐµÐ½Ð½Ð¾ÑÑÐ¸ Ð±ÐµÐ»ÐºÐ¾Ð² Ð¿Ð¾ÐºÐ°Ð·Ð°Ð»Ð¸, ÑÑÐ¾ Ð±ÐµÐ»Ð¾Ðº NP(-) Ð¿ÑÐ¸ Ð¸Ð½ÑÑÐ°Ð½Ð°Ð·Ð°Ð»ÑÐ½Ð¾Ð¼ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ð¸ Ð¼ÑÑÐ°Ð¼ Ð¸Ð½Ð´ÑÑÐ¸ÑÐ¾Ð²Ð°Ð» Ð²ÑÑÐ¾ÐºÐ¸Ð¹ ÑÑÐ¾Ð²ÐµÐ½Ñ Ð²ÑÑÐ°Ð±Ð¾ÑÐºÐ¸ ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð°Ð½ÑÐ¸ÑÐµÐ», Ð° ÑÐ°ÐºÐ¶Ðµ Ð¾Ð±ÐµÑÐ¿ÐµÑÐ¸Ð» Ð´Ð¾ÑÑÐ°ÑÐ¾ÑÐ½ÑÑ Ð·Ð°ÑÐ¸ÑÑ Ð¿ÑÐ¸ Ð»ÐµÑÐ°Ð»ÑÐ½Ð¾Ð¼ Ð·Ð°ÑÐ°Ð¶ÐµÐ½Ð¸Ð¸ Ð²Ð¸ÑÑÑÐ°Ð¼Ð¸ Ð³ÑÐ¸Ð¿Ð¿Ð° Ð/H1N1 A/H3N2. Ð ÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÐµ Ð±ÐµÐ»ÐºÐ¸ NP(255), NP(335) Ð¸ NP(335+255) Ð¿ÑÐ¸ Ð¸Ð½ÑÑÐ°Ð½Ð°Ð·Ð°Ð»ÑÐ½Ð¾Ð¼ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ð¸ ÑÑÐ¸Ð¼ÑÐ»Ð¸ÑÐ¾Ð²Ð°Ð»Ð¸ ÑÐ»Ð°Ð±Ð¾Ðµ ÑÐ¾ÑÐ¼Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð°Ð½ÑÐ¸ÑÐµÐ» Ð¸ Ð¸Ð¼ÐµÐ»Ð¸ Ð½Ð¸Ð·ÐºÑÑ Ð¿ÑÐ¾ÑÐµÐºÑÐ¸Ð²Ð½ÑÑ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ. ÐÐ´ÑÑÐ²Ð°Ð½Ñ Sepivac SWE ÑÑÐ¸Ð»Ð¸Ð» Ð¸Ð¼Ð¼ÑÐ½Ð¾Ð³ÐµÐ½Ð½Ð¾ÑÑÑ Ð±ÐµÐ»ÐºÐ° NP(335) Ð¿ÑÐ¸ Ð²Ð½ÑÑÑÐ¸Ð¼ÑÑÐµÑÐ½Ð¾Ð¼ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ð¸.
description: The subject of the graduate qualification work is Â«Characterization of SAP-based recombinant proteins carrying conserved fragments of influenza A virus proteinsÂ». In this study the ectodomain of protein M2 (M2e), HA76-130 fragment and two regions of NP protein (NP255-275 Ð¸ NP335-350) were chosen as targeted antigens. Based on antigen recombination four version of SAP-based recombinant proteins were constructed designated as NP(-), NP(255), NP(335) and NP(335+255). Physico-chemical characterization was conducted. Results of secondary and tertiary structure prediction showed that the structure of SAP and ÐÐ fragments in recombinant proteins are not fully aligned with literature data. The hydrodynamic diameter of the particles formed by proteins ranged from 47 to 107 nm. It was shown that proteins had a sufficient degree of purification and proteins molecular weight according to their electrophoretic mobility complied with its theoretical molecular weight. Immunogenicity research shown that the intranasal administration of Â NP(-) protein stimulated strong antibodie-mediated immune response and provides complete protection of mice infected with a lethal dose of the H3N2 and H1N1 subtype virus. The intranasal administration of NP(255) and NP(335+255) proteins induced poor formation of specific antibodies and did not provide protection against lethal infection. The significant T-cell response formation was not detected. NP(335) protein administrated intranasally showed low immunogenicity. Sepivac SWE adjuvant enhanced NP(335) protein immunogenicity following intramuscular administration.